Kenvue stock rebounds: Tylenol maker rises 6% after Donald Trump’s autism claims; analysts see limited legal impact
Join our WhatsApp Community to receive travel deals, free stays, and special offers!
- Join Now -
Join our WhatsApp Community to receive travel deals, free stays, and special offers!
- Join Now -
Kenvue shares rebounded after a sharp fall triggered by Donald Trump's unfounded claims linking Tylenol to autism. Trump advised pregnant women to avoid the drug, despite a lack of new scientific evidence. Kenvue refuted the claims, while an analyst predicted limited lawsuit risks but cautioned about potential consumption decline due to negative publicity. What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
